A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
Running, not enrolling · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Influenza A
In brief
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Key facts
- Study ID
- NCT07128615
- Run by
- AstraZeneca
- People needed
- 405
- Starts
- 2025-09-04
- Expected to finish
- 2026-12-29
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Long Beach, California, United States
- Research Site — Rolling Hills Estates, California, United States
- Research Site — Hialeah, Florida, United States
- Research Site — Stockbridge, Georgia, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Lenexa, Kansas, United States
- Research Site — Kansas City, Missouri, United States
- Research Site — Omaha, Nebraska, United States
- Research Site — Las Vegas, Nevada, United States
- Research Site — Cincinnati, Ohio, United States
- Research Site — Edmond, Oklahoma, United States
- Research Site — North Charleston, South Carolina, United States
- Research Site — Austin, Texas, United States
- Research Site — West Jordan, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.